ArticleJournal of diabetes science and technology2015
Parsimonious Description of Glucose Variability in Type 2 Diabetes by Sparse Principal Component Analysis.
Article in Journal of diabetes science and technology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- A daily study of stressors, continuously measured glucose, and diabetes symptoms in latinos with type 2 diabetes.Journal of behavioral medicine · 2021Trial
- Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.BioMed research international · 2021Trial
- Assessment of Glucose Control Metrics by Discriminant Ratio.Diabetes technology & therapeutics · 2020Trial
- Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.Scientific reports · 2018Trial
- Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy.Scientific reports · 2018Trial
- Article
- Heterogeneity of continuous glucose monitoring features and their clinical associations in a type 2 diabetes population.Diabetes, obesity & metabolism · 2025Article
- Profiles of Intraday Glucose in Type 2 Diabetes and Their Association with Complications: An Analysis of Continuous Glucose Monitoring Data.Diabetes technology & therapeutics · 2021Article
- Interpreting blood GLUcose data with R package iglu.PloS one · 2021Article
- Simple Linear Support Vector Machine Classifier Can Distinguish Impaired Glucose Tolerance Versus Type 2 Diabetes Using a Reduced Set of CGM-Based Glycemic Variability Indices.Journal of diabetes science and technology · 2020Article
- Decreased complexity of glucose dynamics in diabetes in rhesus monkeys.Scientific reports · 2019Article
- A dashboard-based system for supporting diabetes care.Journal of the American Medical Informatics Association : JAMIA · 2018Article
- Investigation of glucose fluctuations by approaches of multi-scale analysis.Medical & biological engineering & computing · 2018Article
- Diabetes and Prediabetes Classification Using Glycemic Variability Indices From Continuous Glucose Monitoring Data.Journal of diabetes science and technology · 2018Article
- Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Article
- Mean Levels and Variability in Affect, Diabetes Self-Care Behaviors, and Continuously Monitored Glucose: A Daily Study of Latinos With Type 2 Diabetes.Psychosomatic medicine · 2017Article
- Features of glycemic variations in drug naïve type 2 diabetic patients with different HbAScientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbnormal glucose variability (GV) is a risk factor for diabetes complications, and tens of indices for its quantification from continuous glucose monitoring (CGM) time series have been proposed. However, the information carried by these indices is redundant, and a parsimonious description of GV can be obtained through sparse principal component analysis (SPCA). We have recently shown that a set of 10 metrics selected by SPCA is able to describe more than 60% of the variance of 25 GV indicators in type 1 diabetes (T1D). Here, we want to extend the application of SPCA to type 2 diabetes (T2D).
methodsA data set of CGM time series collected in 13 T2D subjects was considered. The 25 GV indices considered for T1D were evaluated. SPCA was used to select a subset of indices able to describe the majority of the original variance.
resultsA subset of 10 indicators was selected and allowed to describe 83% of the variance of the original pool of 25 indices. Four metrics sufficient to describe 67% of the original variance turned out to be shared by the parsimonious sets of indices in T1D and T2D.
conclusionsStarting from a pool of 25 indices assessed from CGM time series in T2D subjects, reduced subsets of metrics virtually providing the same information content can be determined by SPCA. The fact that these indices also appear in the parsimonious description of GV in T1D may indicate that they could be particularly informative of GV in diabetes, regardless of the specific type of disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.